People who experience psychosis may produce too much or even too little cannabinoids (from overactive dopamine receptors). CBD is milder than our internal cannabinoids and helps to re-establish a balance of cannabinoids in the brain. CBD also helps lower inflammation, which is often increased in schizophrenia. THC, on the other hand, is stronger than our internal cannabinoids (anandamide and 2-AG), this way potentially triggering psychosis [46, 48].
CBD shows promise in the treatment of anxiety disorders, according to a report published in the journal Neurotherapeutics in 2015. Looking at results from experimental research, clinical trials, and epidemiological studies, the report’s authors found evidence that CBD may help treat generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. However, the authors caution that human-based research on CBD and anxiety is fairly limited at this point.
In fact, the U.S. Food and Drug Administration (FDA) approved Epidiolex (a drug made with a purified form of CBD oil) in June 2018 for the treatment of seizures associated with two rare and severe forms of epilepsy in patients 2 years of age and older. These two epilepsy forms are known as Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex is the first FDA-approved drug that contains a purified drug substance derived from marijuana.